MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Xencor Inc

Fermé

SecteurSoins de santé

10.59

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.17

Max

10.88

Chiffres clés

By Trading Economics

Revenu

-5.7M

-54M

Ventes

59M

70M

BPA

-0.62

Marge bénéficiaire

-77.303

Employés

250

EBITDA

27M

-16M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+178.3% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-370M

747M

Ouverture précédente

10.59

Clôture précédente

10.59

Score Technique

By Trading Central

Confiance

Bullish Evidence

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2025, 23:53 UTC

Actions en Tendance

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29 avr. 2025, 23:06 UTC

Résultats

Prudential PLC 1Q New Business Profit Increases by 12%

29 avr. 2025, 23:00 UTC

Résultats

America Movil's Posts Rise in 1Q Profit, Revenue

29 avr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29 avr. 2025, 23:43 UTC

Market Talk

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29 avr. 2025, 23:41 UTC

Résultats

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29 avr. 2025, 23:41 UTC

Résultats

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29 avr. 2025, 23:41 UTC

Résultats

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29 avr. 2025, 23:24 UTC

Résultats

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29 avr. 2025, 23:24 UTC

Résultats

China Vanke 1Q Loss Widened Significantly >000002.SZ

29 avr. 2025, 23:15 UTC

Actualités

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29 avr. 2025, 23:14 UTC

Résultats

China Eastern Airlines 1Q Loss Widened >0670.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines Swung to Loss in 1Q>1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29 avr. 2025, 23:11 UTC

Résultats

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29 avr. 2025, 23:07 UTC

Résultats

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29 avr. 2025, 23:07 UTC

Résultats

Air China 1Q Losses Widened>0753.HK

29 avr. 2025, 23:07 UTC

Résultats

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29 avr. 2025, 23:02 UTC

Résultats

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29 avr. 2025, 23:02 UTC

Résultats

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29 avr. 2025, 23:02 UTC

Résultats

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

29 avr. 2025, 22:56 UTC

Résultats

COSCO SHIPPING Holdings: Higher Contributions From Constainer Shipping Business Supported Results>1919.HK

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

178.3% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD  178.3%

Haut 38 USD

Bas 22 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

9

Achat

0

Maintien

1

Vente

Score Technique

By Trading Central

9.54 / 10.65Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.